World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
31121
World Ranking
17846
National Ranking
275

Jerome B. Zeldis publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jerome B. Zeldis sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 300 publications — 17th percentile

17% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jerome B. Zeldis D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jerome B. Zeldis sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jerome B. Zeldis is affiliated with Bristol-Myers Squibb (Switzerland) in Switzerland and focuses their research primarily within the field of Medicine. Their work spans several subfields including Oncology, Infectious Diseases, Immunology, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

The scientist has contributed to multiple aspects of biomedical research, with main topics that encompass:

  • CAR-T cell therapy research
  • Monoclonal and Polyclonal Antibodies Research
  • SARS-CoV-2 and COVID-19 Research
  • PARP inhibition in cancer therapy
  • Viral Infections and Outbreaks Research
  • Parasitic Diseases Research and Treatment
  • Parasite Biology and Host Interactions

Their publications demonstrate a focus on immunotherapy, viral disease research, and parasitic disease treatment. Recent papers include:

  • The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro, 2020, F1000Research
  • Filarial nematode phenotypic screening cascade to identify compounds with anti-parasitic activity for drug discovery optimization, 2022, International Journal for Parasitology Drugs and Drug Resistance
  • AIM™ platform: A new immunotherapy approach for viral diseases, 2022, Frontiers in Medicine
  • Abstract 2188: Generation and characterization of human placental-derived CD19 CAR-T cells using viral vectors, 2020, Cancer Research
  • Prior Antigen Exposure Enhances the T Cell Response to Bispecific T Cell Engager Therapy, 2023, Transplantation and Cellular Therapy

The scientist frequently collaborates with peers including Ruipeng Wang, Mathias Oelke, Keshanti Tidwell, Adam R. Parks, and Shweta Jain.

Jerome B. Zeldis has published in a variety of journals, illustrating a multidisciplinary approach, with frequent publication venues such as:

  • F1000Research
  • International Journal for Parasitology Drugs and Drug Resistance
  • Frontiers in Medicine
  • Cancer Research
  • Transplantation and Cellular Therapy

Best Publications

  • Antitumor activity of thalidomide in refractory multiple myeloma.

    S Singhal;J Mehta;R Desikan;D Ayers

  • Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Meletios Dimopoulos;Andrew Spencer;Michael Attal;H. Miles Prince

  • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

    Alan List;Gordon Dewald;John Bennett;Aristotle Giagounidis

  • Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

    Donna M. Weber;Christine Chen;Ruben Niesvizky;Michael Wang

  • Efficacy of lenalidomide in myelodysplastic syndromes.

    Alan List;Sandy Kurtin;Denise J. Roe;Andrew Buresh

  • Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

    Paul G. Richardson;Robert L. Schlossman;Robert L. Schlossman;Edie Weller;Edie Weller;Teru Hideshima;Teru Hideshima

  • Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

    Bart Barlogie;Raman Desikan;Raman Desikan;Paul Eddlemon;Paul Eddlemon;Trey Spencer;Trey Spencer

  • A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

    Paul G. Richardson;Emily Blood;Constantine S. Mitsiades;Sundar Jagannath

  • Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

    Azra Raza;James A. Reeves;Eric J. Feldman;Gordon W. Dewald

  • Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

    M A Dimopoulos;C Chen;A Spencer;R Niesvizky

  • Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

    Peter H. Wiernik;Izidore S. Lossos;Joseph M. Tuscano;Glen Justice

  • Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma

    S. Vincent Rajkumar;Laura Rosiñol;Mohamad Hussein;John Catalano

  • A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

    Ruben A. Mesa;David P. Steensma;David P. Steensma;Animesh Pardanani;Animesh Pardanani;Chin Yang Li;Chin Yang Li

  • Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network

    Antonio Palumbo;Patrizia Falco;Paolo Corradini;Antonietta Falcone

  • Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

    Thomas E. Witzig;Peter H. Wiernik;Timothy Moore;Craig Reeder

  • An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

    Eric A. Vasiliauskas;Lori Y. Kam;Maria T. Abreu-Martin;Philip V. Hassard

  • Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

    Michael Wang;Luis Fayad;Nicolaus A Wagner-Bartak;Liang Zhang

  • Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.

    Thomas M. Habermann;Izidore S. Lossos;Glen Justice;Julie M. Vose

  • Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.

    Nianhang Chen;Henry Lau;Linghui Kong;Gondi Kumar

  • Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

    Ayalew Tefferi;Jorge E Cortes;Jorge E Cortes;Jorge E Cortes;Srdan Verstovsek;Srdan Verstovsek;Srdan Verstovsek;Ruben A. Mesa;Ruben A. Mesa;Ruben A. Mesa

Frequent Co-Authors

Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
David C. Seldin
David C. Seldin Boston University
Edward A. Stadtmauer
Edward A. Stadtmauer University of Pennsylvania
Julie M. Vose
Julie M. Vose University of Nebraska Medical Center
Gilla Kaplan
Gilla Kaplan Bill & Melinda Gates Foundation
Andrew Spencer
Andrew Spencer Monash University
Rob Knight
Rob Knight University of California, San Diego
Maurizio Zangari
Maurizio Zangari University of Arkansas for Medical Sciences

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in studying medicine in the USA, you may also want to explore related online degrees that can open up diverse career paths in healthcare. Cheapest online healthcare administration degree programs offer a flexible way to enter healthcare leadership roles without the high cost or need to relocate.

For those seeking more advanced opportunities, the cheapest online master degree in healthcare administration can boost your credentials and prepare you for upper management positions.

If you’re considering advanced clinical practice, exploring most affordable online dnp programs can be a strategic step in becoming a Doctor of Nursing Practice, allowing for greater patient impact and leadership potential.

Pharmacy is another high-demand field. Pursuing a pharmacy degree online is becoming increasingly accessible and can prepare you for vital roles in medication management, research, and patient care.

These online pathways provide flexibility, affordability, and a strong foundation for those interested in health and medicine outside of the traditional MD track.

Best Scientists Citing Jerome B. Zeldis

Trending Scientists

Recently Published Articles